<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2019.911202</article-id><article-id pub-id-type="publisher-id">ACM-33074</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20191100000_44397716.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  脊柱关节炎肌腱端炎病理生理机制的研究进展
  Research Progress in Pathophysiological Mechanism of Enthesitis in Spondyloarthritis
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>丁</surname><given-names>泓百</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>朱</surname><given-names>琦</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>上海中医药大学，上海</addr-line></aff><aff id="aff3"><addr-line>上海中医药大学附属光华医院，关节内科，上海</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>31</day><month>10</month><year>2019</year></pub-date><volume>09</volume><issue>11</issue><fpage>1306</fpage><lpage>1314</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   目的：肌腱端是脊柱关节炎(SpA)这类疾病中骨骼炎症的主要靶点之一。过去的研究低估了SpA中肌腱端炎的发病率，近些年随着影像仪器的发展，无临床症状的肌腱端炎能够被诊断出。对肌腱端炎发病机制的研究有利于制定SpA疾病的早期诊断和治疗策略。方法：检索近几年国内外关于肌腱端炎的文献，进行总结分析。结果：发现SpA肌腱端炎的病理生理机制包括：机械应激与免疫激活、间充质干细胞增殖以及新骨形成。结论：若能说明肌腱端炎与新骨形成的具体联系，将会对脊柱关节炎的治疗有很大启发。 Objective: The entheses is one of the main targets of the bone inflammation in the disease such as Spondyloarthritis (SpA). In the past, the incidence of enthesitis in SpA has been underestimated. In recent years, with the development of the image instrument, enthesitis without clinical symptoms can be diagnosed. The study of the pathogenesis of the enthesitis is beneficial to the development of early diagnosis and treatment strategies of SpA disease. Methods: The literature on the enthesitis at home and abroad in recent years was searched, and the summary and analysis were carried out. Results: The pathological and physiological mechanism of the enthesitis of SpA was found to include the mechanical stress and the immune activation, the proliferation of the mesenchymal stem cells and the formation of new bone. Conclusion: It is a great inspiration for the treatment of SpA if the specific relationship between the enthesitis and the formation of the new bone is indicated. 
  
 
</p></abstract><kwd-group><kwd>脊柱关节炎，肌腱端炎，机制, Spondyloarthritis</kwd><kwd> Enthesitis</kwd><kwd> Mechanism</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>脊柱关节炎肌腱端炎病理生理机制的研究进展<sup> </sup></title><p>丁泓百<sup>1*</sup>，朱琦<sup>2#</sup></p><p><sup>1</sup>上海中医药大学，上海</p><p><sup>2</sup>上海中医药大学附属光华医院，关节内科，上海</p><disp-formula id="hanspub.33074-formula37"><graphic xlink:href="//html.hanspub.org/file/13-1571075x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2019年11月1日；录用日期：2019年11月14日；发布日期：2019年11月21日</p><disp-formula id="hanspub.33074-formula38"><graphic xlink:href="//html.hanspub.org/file/13-1571075x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：肌腱端是脊柱关节炎(SpA)这类疾病中骨骼炎症的主要靶点之一。过去的研究低估了SpA中肌腱端炎的发病率，近些年随着影像仪器的发展，无临床症状的肌腱端炎能够被诊断出。对肌腱端炎发病机制的研究有利于制定SpA疾病的早期诊断和治疗策略。方法：检索近几年国内外关于肌腱端炎的文献，进行总结分析。结果：发现SpA肌腱端炎的病理生理机制包括：机械应激与免疫激活、间充质干细胞增殖以及新骨形成。结论：若能说明肌腱端炎与新骨形成的具体联系，将会对脊柱关节炎的治疗有很大启发。</p><p>关键词 :脊柱关节炎，肌腱端炎，机制</p><disp-formula id="hanspub.33074-formula39"><graphic xlink:href="//html.hanspub.org/file/13-1571075x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2019 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/13-1571075x8_hanspub.png" /> <img src="//html.hanspub.org/file/13-1571075x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>脊柱关节炎(SpA)是一组表现为中轴关节、外周关节和关节周围病变的血清类风湿因子阴性的疾病，包括强直性脊柱炎(AS)、银屑病关节炎(PsA)、反应性关节炎(ReA)、肠病性关节炎、幼年发病的脊柱关节病(JSpA)和未分化脊柱关节病(uSpA)。肌腱端炎是SpA的一种重要而常见的表现形式，特别是PsA和AS。随着医学免疫和影像仪器的发展，肌腱端炎受到越来越多的关注和重视。肌腱端包含一种特定的免疫微环境，肌腱端炎由多种因素共同激活，包括机械应激、遗传易感性和微生物诱导的免疫激活。综述主要讨论机械应激与免疫激活诱导的炎症反应，以及之后的新骨形成在SpA肌腱端炎中的病理生理作用。</p></sec><sec id="s4"><title>2. 肌腱端的结构与生理功能</title><p>肌腱端是一种独特的解剖结构，指肌腱或韧带插入骨表面的部位，与关节内的滑膜不同，肌腱端通常位于关节外，它能够使肌腱或韧带稳定地锚定在骨表面，并且把机械压力从肌肉传递给骨骼，是机体运动的基础 [<xref ref-type="bibr" rid="hanspub.33074-ref1">1</xref>]。肌腱与骨连接处承重的特殊力学性能依赖于其微观结构和微观力学的复杂相互作用，其中一个关键的500 μm厚的过渡区，也称为纤维软骨，包含了散在分布成纤维细胞的纤维丰富区和带有软骨基质的软骨细胞区，这种纤维和软骨组织元素的混合物同时提供了硬度和弹性，满足了肌腱端的高级机械需求 [<xref ref-type="bibr" rid="hanspub.33074-ref2">2</xref>]。肌腱端的营养主要是依靠它邻近骨髓中的血液供给，这里的骨骼薄而多孔，因此可以让血液顺利流出 [<xref ref-type="bibr" rid="hanspub.33074-ref3">3</xref>]。</p></sec><sec id="s5"><title>3. 肌腱端炎的诱导和炎症反应</title><p>机械应激可能是诱导肌腱端炎的主要因素，其包括运动引起的肌腱端炎以及与自身免疫相关的肌腱端炎。</p><sec id="s5_1"><title>3.1. 机械应激</title><p>肌腱端炎可能是由于反复的机械超负荷引起的。运动引起的肌腱端炎是独立的、有自限性的，例如“网球肘”和“高尔夫球肘”；然而，SpA中的肌腱端炎往往是呈慢性的、多发的 [<xref ref-type="bibr" rid="hanspub.33074-ref4">4</xref>]。但是，目前还没有确切的证据证明SpA中的肌腱端炎与机械超负荷引起的肌腱端炎有本质上的不同。Schett等 [<xref ref-type="bibr" rid="hanspub.33074-ref5">5</xref>] 给出的假设是：SpA患者引发肌腱端炎的阈值比健康正常人要低得多，这就允许在很少或没有机械压力的情况下发展为肌腱端炎，类似于对低水平机械应力的过度反应。</p><p>SpA的特征性炎症多发生在骶髂关节、脊柱和肌腱端的软骨与骨的交界处，机械应激可能对引发甚至维持炎症有重要作用，并能解释为什么SpA最影响骨骼的承重部位。Jacques等 [<xref ref-type="bibr" rid="hanspub.33074-ref6">6</xref>] 发现：与后肢负重的TNF<sup>ΔARE</sup>小鼠相比，尾悬吊小鼠未出现临床肌腱端炎征象，选择性Erk1/2/MEK1抑制剂可以干扰肌腱端炎的发展，证明MAPK/Erk信号通路参与了TNF<sup>ΔARE</sup>小鼠的肌腱端炎的发生发展。临床观察与小鼠实验都表明：机械应激是诱发肌腱端炎的主要因素之一，但其确切的分子机制仍不确定。前列腺素E2 (PGE2)是炎症早期重要的介导因子。Paulissen等 [<xref ref-type="bibr" rid="hanspub.33074-ref7">7</xref>] 的实验中，用COX-2抑制剂：塞来昔布治疗Th17介导的滑膜炎后，PGE2和白细胞介素(IL) 17A水平显著降低，表明COX-2/PGE2通路在炎症性疾病中起着关键作用。Bergqvist等 [<xref ref-type="bibr" rid="hanspub.33074-ref8">8</xref>] 对有肌腱病变患者的跟腱进行了研究，结果发现：PGE2具有维持炎症和疼痛的作用，而前列环素可能对肌腱有保护作用。</p><p>因此，可以认为机械应激诱发的肌腱端炎的分子机制与COX-2/PGE2通路有关。</p></sec><sec id="s5_2"><title>3.2. 固有免疫反应</title><sec id="s5_2_1"><title>3.2.1. IL-17A</title><p>IL-17超家族由6个配体(IL-17A至IL-17F)组成，可与5个受体亚型(IL-17RA至IL-17RE)结合。其中IL-17A是IL-17家族中最具特征性的一员，在皮肤、关节和肌腱端相关的临床表现中发挥着重要作用 [<xref ref-type="bibr" rid="hanspub.33074-ref9">9</xref>]。IL-17A与受体结合时，通过诱导新基因转录或稳定促炎细胞因子和趋化因子的mRNA来上调炎症基因的表达 [<xref ref-type="bibr" rid="hanspub.33074-ref10">10</xref>]。产生IL-17的CD4+炎性Th17细胞在炎症性疾病的发生中起着关键作用，而IL-23对Th17细胞亚群的扩增和功能活性有重要意义 [<xref ref-type="bibr" rid="hanspub.33074-ref11">11</xref>]。最近的研究指出，产生IL-17的γδT细胞在炎症性疾病中具有额外的作用，该细胞表达IL-23受体(IL-23R)，且在SpA患者外周血中富集 [<xref ref-type="bibr" rid="hanspub.33074-ref12">12</xref>]。</p><p>一个关键的问题是要确定所有产生IL-17A的细胞群，特别是在SpA的肌腱端中。最近，ILC 3和γδT细胞群首次在人类肌腱端中被发现，在那里他们可能产生IL-17A，从而驱动肌腱端炎 [<xref ref-type="bibr" rid="hanspub.33074-ref13">13</xref>]。</p></sec><sec id="s5_2_2"><title>3.2.2. γδT细胞</title><p>在诱导炎症反应和IL-23过度表达的小鼠实验中，研究者用双光子显微镜观察到：在未发炎的肌腱端中存在大量活化的γδT细胞，它们构成了肌腱端常驻淋巴细胞的绝大部分；在炎症条件下，跟腱端γδT细胞大量增加 [<xref ref-type="bibr" rid="hanspub.33074-ref14">14</xref>]。此外，胎儿胸腺依赖性γδT细胞是肌腱端IL-17A的主要来源。这说明：γδT细胞来源于胎儿胸腺，是一种自我更新的组织常驻细胞。γδT细胞作为机体内主要的IL-17A生成因子，在IL-23诱导的局部炎症的发病机制中起着重要的作用 [<xref ref-type="bibr" rid="hanspub.33074-ref14">14</xref>]。</p></sec><sec id="s5_2_3"><title>3.2.3. 3型固有淋巴细胞(ILC3s)</title><p>ILC3s在肠道和皮肤等屏障组织中起着重要的作用，这两个组织也是SpA的重要靶组织。那么作为SpA的另一重要靶组织——肌腱端，也存在一定量的ILC3s，并且肌腱端中ILCs的比例高于外周血。用IL-23和IL-1β刺激肌腱端，正常的肌腱端IL-17A转录因子表达上调，受损的肌腱端的组织学检查显示存在维甲酸受体相关的孤儿核受体γt (RORγt)，说明ILC3s有可能参与SpA的发病过程 [<xref ref-type="bibr" rid="hanspub.33074-ref15">15</xref>]。此外，ILCs被证明能驱动小鼠中IL-23依赖的肠道炎症 [<xref ref-type="bibr" rid="hanspub.33074-ref16">16</xref>]，并在炎症性肠病(IBD)患者的肠道中富集 [<xref ref-type="bibr" rid="hanspub.33074-ref17">17</xref>]。</p></sec><sec id="s5_2_4"><title>3.2.4. IL-23</title><p>Charlie等 [<xref ref-type="bibr" rid="hanspub.33074-ref18">18</xref>] 通过对人类肌腱端周围骨组织(PEB)和软组织(ST)进行流式细胞术分析发现：肌腱端存在能够产生IL-23的髓系细胞，并且几乎所有的IL-23都来自CD14+的髓系细胞，而不是CD14−的部分，这突出了该髓系细胞群体在SpA疾病启动中的潜在重要性；此外，细菌和真菌佐剂均能诱导CD14+的髓系细胞产生IL-23；磷酸二酯酶4抑制剂(PDE4I)和其他环磷酸腺苷(cAMP)升高剂被证明可抑制SpA肌腱端和血液中的CD14+髓系细胞产生IL-23。PDE4抑制剂和IL-23阻滞剂对SpA有疗效，但对RA无效。</p><p>活体显微镜显示：肌腱端中含有大量的常驻IL23R+T细胞群，允许组织快速与IL-23发生反应，有趣的是这些细胞只存在于肌腱端，而滑膜和肌腱中不存在。这些细胞表达了分子早幼粒细胞白血病锌指蛋白(PLZF)，它允许它们非常迅速地对细胞因子起反应，在体外实验中肌腱端也能够在数小时内对IL-23发生反应。此外，小鼠体内IL-23的表达本身也足以快速诱导脊柱关节炎的标志性特征的产生，其中就包括肌腱端炎 [<xref ref-type="bibr" rid="hanspub.33074-ref19">19</xref>]。</p></sec><sec id="s5_2_5"><title>3.2.5. IL-23/IL-17轴</title><p>Sherlock等 [<xref ref-type="bibr" rid="hanspub.33074-ref20">20</xref>] 人的实验结果表明，IL-23通过作用于少量IL-23R(+)，ROR-γt(+)CD3(+)CD4(−)CD8(−)的肌腱端常驻T细胞，介导SpA的特征性炎症。IL-23/IL-17轴的含义也得到了以下结果的支持：至少有6个axSpA相关的非MHC位点与该通路中的基因(RUNX3, IL23R, IL6R, IL1R2, IL12B, TYK2)相关 [<xref ref-type="bibr" rid="hanspub.33074-ref21">21</xref>]。</p><p>虽然IL-23的治疗性阻滞对PsA有疗效，但在AS患者的一项临床试验的结果却令人失望 [<xref ref-type="bibr" rid="hanspub.33074-ref22">22</xref>]。最近的一篇文章使用的HLA-B27大鼠模型表明SpA病理是依赖于IL-23来启动的，而不是使SpA疾病持续存在。这可能表明IL-17独立于IL-23促进SpA疾病进展，而IL-23是SpA疾病引发所必需的引子 [<xref ref-type="bibr" rid="hanspub.33074-ref23">23</xref>]。</p><p>综上所述，这些数据提示SpA的肌腱端炎的初始炎症反应可能是不同类型免疫细胞的复杂相互作用的结果，IL-23/IL-17通路可能在其慢性炎症中起关键作用。</p></sec></sec></sec><sec id="s6"><title>4. 肌腱端炎的新骨形成</title><p>新骨形成可能是达到肌腱端炎高峰后开始的组织反应过程。这一过程可能是由间充质干细胞(MSCs)启动的，这些细胞有潜能增殖和分化为软骨细胞和成骨细胞，从而形成软骨和骨 [<xref ref-type="bibr" rid="hanspub.33074-ref24">24</xref>]。在增殖和分化过程中可能受到以下几种通路的影响：</p><sec id="s6_1"><title>4.1. BMP信号通路</title><p>骨形态发生蛋白(BMPs)是一种可外生诱导软骨下骨形成的蛋白质，在骨骼和关节形态发生中起着至关重要的作用 [<xref ref-type="bibr" rid="hanspub.33074-ref25">25</xref>]。BMPs主要位于骨髓基质细胞、骨膜细胞和骨细胞内 [<xref ref-type="bibr" rid="hanspub.33074-ref26">26</xref>]。BMPs是TGF-β超家族的成员，能够调节细胞的增殖、分化、确定谱系、运动和死亡等细胞过程 [<xref ref-type="bibr" rid="hanspub.33074-ref27">27</xref>]。在经典途径中，BMPs诱导配体依赖的I型和II型受体，导致Smad信号分子(Smad 1/5)磷酸化，结合Smad4，然后转移到细胞核中。</p><p>Lories等的研究表明，在脊柱关节炎的小鼠模型中，BMPs参与肌腱端骨形成，运用BMPs细胞外拮抗药物noggin后，内源性BMPs水平降低，延缓了关节软骨向骨形成的转化。noggin已经被证明是BMP2/4、BMP5/6/7的拮抗剂，noggin过表达很可能改变BMP信号的总体平衡 [<xref ref-type="bibr" rid="hanspub.33074-ref28">28</xref>]。为了特别测试在小鼠中的发现是否与人类疾病中新骨形成相关，Lories等还研究了脊柱关节炎患者的跟腱端的BMP信号，结果显示与小鼠模型非常相似 [<xref ref-type="bibr" rid="hanspub.33074-ref29">29</xref>]。他们的数据显示在疾病早期可于成纤维细胞和软骨样细胞中检测到BMP2，而在后期，BMP7主要限于肥大软骨细胞前体，BMP6存在于肥大软骨细胞中。</p><p>最新研究表示，肝脏中控制铁稳态的转铁蛋白受体2 (Tfr2)，还是一种抑制骨形成的骨稳态调节因子。骨髓移植实验和对小鼠细胞特异性Tfr2基因敲除的研究表明，Tfr2能抑制BMP-p38MAPK信号转导，降低Wnt抑制剂骨硬化蛋白(SOST)在成骨细胞中的特异性表达，并证明了Tfr2的胞外结构域作为诱饵受体与BMPs结合，然后抑制了BMP-2诱导的异位骨化，因此，Tfr2胞外区可能是治疗与病理骨形成相关疾病的关键点 [<xref ref-type="bibr" rid="hanspub.33074-ref30">30</xref>]。</p></sec><sec id="s6_2"><title>4.2. Wnt/β-catenin信号通路</title><p>Wnt是在哺乳动物中具有19种蛋白质家族的分泌糖蛋白，包括Wnt3a和Wnt10b，其中Wnt10b刺激成骨转录因子Runx2，从而促进成骨细胞生成和骨形成 [<xref ref-type="bibr" rid="hanspub.33074-ref31">31</xref>]。Wnt配体可通过β-catenin依赖或β-catenin独立通路发出信号，在没有Wnt配体的情况下，β-catenin被复合物糖原合成酶激酶3(GSK3)降解 [<xref ref-type="bibr" rid="hanspub.33074-ref32">32</xref>]。因此，GSK3是Wnt/β-catenin途径的负调节物。稳定的β-catenin在细胞核中积累，并与淋巴增强结合因子/T细胞特异性转录因子(LEF/TCF)结合以激活靶基因转录 [<xref ref-type="bibr" rid="hanspub.33074-ref33">33</xref>]。因此，β-catenin是Wnt途径的关键信号传导因子。</p><p>Wnt/β-catenin信号正调节成骨细胞分化和骨形成。成骨细胞分化过程中β-catenin表达增加，在成骨细胞分化晚期缺失β-catenin则会导致骨成熟和矿化受损 [<xref ref-type="bibr" rid="hanspub.33074-ref34">34</xref>]。Wnt通路对骨形成的作用也受到包括Dickkopfs(Dkks)、SOST和分泌卷曲蛋白受体(sFRP)在内的Wnt拮抗剂的调节 [<xref ref-type="bibr" rid="hanspub.33074-ref35">35</xref>]。目前研究者已经证明Dkk1拮抗经典Wnt信号并与骨质量反向相关，Dkk2除了拮抗经典Wnt信号传导外，还在成骨细胞分化终末期和矿化基质形成中起作用 [<xref ref-type="bibr" rid="hanspub.33074-ref36">36</xref>]。与对照组小鼠相比，SpIPG小鼠的脊柱中Dkk1和SOST表达水平降低，证明过度的骨形成与Wnt抑制剂减少有关 [<xref ref-type="bibr" rid="hanspub.33074-ref37">37</xref>]。与类风湿关节炎(RA)患者或健康人的血清相比，AS患者血清中的DKK-1浓度较低，有新骨赘形成的患者血清中DKK1浓度更低，这表示通过DKK1阻止Wnt信号通路可能抑制新骨形成、骨赘生长和关节强直 [<xref ref-type="bibr" rid="hanspub.33074-ref38">38</xref>]。</p></sec><sec id="s6_3"><title>4.3. Hh (Hedgehog)信号通路</title><p>Hh信号通路在骨发育和体内平衡中起着许多重要作用。该途径需要一个特别的细胞器——纤毛。Hh结合蛋白Ptc同系物1 (Ptch1)位于纤毛中，而跨膜蛋白Smoothened (Smo)在没有Hh配体的情况下保持在纤毛外。胶质瘤相关癌基因家族成员(Gli)被激酶磷酸化，Gli通过鞭毛内运输(IFT)从纤毛的顶端被运输到细胞质中，然后转移至细胞核以转录靶基因，从而激活Hh信号传导 [<xref ref-type="bibr" rid="hanspub.33074-ref39">39</xref>]。</p><p>这些Gli1细胞是构建矿化纤维软骨的关键细胞，其活性似乎受到肌肉负荷的控制。在人类中Hh与病理骨形成的关系并不是确定的，但在小鼠模型中有一定的关联。在C57/BL6小鼠中由血清转移诱导的肌腱端炎模型中，阻断Hh途径(使用Smo信号传导途径作为靶标)抑制骨赘的形成，这种抑制不会影响炎症，但会减少局部和全身水平的骨骼结构的破坏 [<xref ref-type="bibr" rid="hanspub.33074-ref40">40</xref>]。此外，Dittmann等 [<xref ref-type="bibr" rid="hanspub.33074-ref41">41</xref>] 的研究表明，脊柱软骨细胞中Hh信号通路的慢性激活可以无需免疫细胞触发强直形态。因此，软骨破坏和轴向联合完整性的丧失可能是由于软骨细胞内在缺陷造成的，似乎绕过了免疫反应。相反的是，Daoussis等 [<xref ref-type="bibr" rid="hanspub.33074-ref42">42</xref>] 发现AS患者印度刺猬蛋白(IHH)水平明显高于RA患者和正常人，抗TNF-α治疗后的AS患者IHH水平明显低于不接受抗TNF-α治疗的AS患者，说明AS患者IHH水平升高，抗TNF-α治疗后IHH水平降低，IHH水平与免疫反应相关。因此，Hh信号通路与免疫的关联性还需要进一步研究。</p></sec><sec id="s6_4"><title>4.4. 甲状旁腺激素相关肽(PTHrP)</title><p>研究发现PTHrP不存在于内在的骨骼细胞中，而是在肌腱端中高表达，PTHrP可能会影响皮下骨细胞群的招募和/或活动，并且机械应力似乎是PTHrP表达的重要调节因子 [<xref ref-type="bibr" rid="hanspub.33074-ref43">43</xref>]。对此，Han等 [<xref ref-type="bibr" rid="hanspub.33074-ref44">44</xref>] 给予小型猪的跟腱端不同的机械压力，通过RT-PCR和Western印迹测量跟腱端纤维软骨细胞中I，II和X型胶原蛋白和PTHrP的表达，发现动态机械应变(MS)可以调节PTHrP的表达，因此作者认为PTHrP可能在纤维软骨细胞分化中起重要作用，并与肌腱端形成和修复相关联。随后，他们研究纤维软骨细胞中Ihh/PTHrP信号通路的调节机制，发现纤维软骨细胞受低循环应力拉伸(CTS)影响，应力刺激通过Ihh/PTHrP信号通路来调节纤维软骨细胞的增殖和分化 [<xref ref-type="bibr" rid="hanspub.33074-ref45">45</xref>]。</p></sec></sec><sec id="s7"><title>5. 药物治疗</title><p>目前对治疗SpA肌腱端炎的研究是有限的。在临床实践中，肌腱端炎的治疗旨在解决炎症，并预防炎症之后引发的组织反应。</p><p>临床观察和超声检测都表明，肌腱端炎对非甾体抗炎药(NSAIDs)的敏感性比滑膜炎高得多，提示PGE 2在肌腱端炎中的主导作用大于滑膜炎 [<xref ref-type="bibr" rid="hanspub.33074-ref46">46</xref>]。NSAIDs能够抑制与肌腱端炎相关的组织反应，因为PGE 2是成骨细胞的一种强有力的诱导剂 [<xref ref-type="bibr" rid="hanspub.33074-ref47">47</xref>]。如果肌腱端炎变成慢性疾病，NSAIDs通常不能充分控制疾病，需要额外的药物。传统的抗风湿药(DMARDs)，如甲氨蝶呤、来氟米特和柳氮磺胺吡啶，似乎不适用于肌腱端炎 [<xref ref-type="bibr" rid="hanspub.33074-ref48">48</xref>]。已被批准用于治疗PsA的磷酸二酯酶4抑制剂：阿普雷斯特(Apremilast)，是目前唯一经证实有效的口服DMARD，阿普斯特能抑制炎症相关细胞因子的产生，如IL-17A、IL-23和TNF，并限制中性粒细胞向炎症部位的迁移 [<xref ref-type="bibr" rid="hanspub.33074-ref49">49</xref>]。</p><p>MRI研究证实肿瘤坏死因子(TNF)抑制剂对中轴型和外周型肌腱端炎都有效 [<xref ref-type="bibr" rid="hanspub.33074-ref50">50</xref>]。此外，肌腱端炎对IL-23和IL-17A的抑制剂反应显著。乌司奴单抗(Ustekinumab)是一种抗IL-12和IL-23共有的p40亚基的抗体，在治疗6个月后，它能有效地治疗约50%的PsA患者的肌腱端炎 [<xref ref-type="bibr" rid="hanspub.33074-ref51">51</xref>]。苏金单抗(Secukinumab)，一种完全人源抗IL-17A单克隆抗体，被批准用于治疗银屑病、PsA和AS，Ixekizumab是一种人源化的抗IL-17A抗体，已被批准用于治疗银屑病和PSA [<xref ref-type="bibr" rid="hanspub.33074-ref52">52</xref>]。但其长期安全性还需要进一步研究，在临床上严格监控。</p></sec><sec id="s8"><title>6. 结语与展望</title><p>随着影像学的发展，特别是超声，SpA中的肌腱端炎的发病率是升高的。大多数研究聚焦于SpA的炎症或新骨形成，但对于二者的联系我们应该加以探索。肌腱端有特殊的结构和作用，且新骨大多生成于此。通过对肌腱端炎的炎症反应期和组织反应期的发生机制的回顾，可以发现机械应力和免疫激活在SpA肌腱端炎的发生发展中有重要作用。这提示在疾病早期，可以通过降低肌腱端机械应力来抑制或减缓炎症反应，在后期，可以通过BMP、WNT等信号通路的抑制剂来抑制或减少新骨形成。今后的研究可能会重点关注：如何通过信号通路中的蛋白或分子早期诊断组织反应期，noggin等抑制剂是否能预防或治疗骨赘形成，从而预防畸形、提高患者的生活质量。</p></sec><sec id="s9"><title>基金项目</title><p>本研究由上海市科委课题(16401930500)、上海市卫健委课题(2016LP050)、2017年度“浦江风湿青年医师培育计划”(SPROG201709)资助。</p></sec><sec id="s10"><title>文章引用</title><p>丁泓百,朱 琦. 脊柱关节炎肌腱端炎病理生理机制的研究进展Research Progress in Pathophysiological Mechanism of Enthesitis in Spondyloarthritis[J]. 临床医学进展, 2019, 09(11): 1306-1314. https://doi.org/10.12677/ACM.2019.911202</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.33074-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Benjamin, M., Toumi, H., Ralphs, J.R., et al. (2006) Where Tendons and Ligaments Meet Bone: Attachment Sites (‘En-theses’) in Relation to Exercise and/or Mechanical Load. Journal of Anatomy, 208, 471-490.  
&lt;br&gt;https://doi.org/10.1111/j.1469-7580.2006.00540.x</mixed-citation></ref><ref id="hanspub.33074-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Rossetti, L., Kuntz, L.A., Kunold, E., et al. (2017) The Microstructure and Micromechanics of the Tendon-Bone Insertion. Nature Materials, 16, 664-670. &lt;br&gt;https://doi.org/10.1038/nmat4863</mixed-citation></ref><ref id="hanspub.33074-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Benjamin, M., Moriggl, B., Brenner, E., et al. (2004) The “Enthesis Organ” Concept: Why Enthesopathies May Not Present as Focal Insertional Disorders. Arthritis &amp; Rheumatism, 50, 3306-3313. &lt;br&gt;https://doi.org/10.1002/art.20566</mixed-citation></ref><ref id="hanspub.33074-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Benjamin, M. and McGonagle, D. (2001) The Anatomical Basis for Disease Localisation in Seronegative Spondyloarthropathy at Entheses and Related Sites. Journal of Anatomy, 199, 503-526.  
&lt;br&gt;https://doi.org/10.1046/j.1469-7580.2001.19950503.x</mixed-citation></ref><ref id="hanspub.33074-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Schett, G., Lories, R.J., D’Agostino, M., et al. (2017) Enthesitis: From Pathophysiology to Treatment. Nature Reviews Rheumatology, 13, 731-741. &lt;br&gt;https://doi.org/10.1038/nrrheum.2017.188</mixed-citation></ref><ref id="hanspub.33074-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Jacques, P., Lambrecht, S., Verheugen, E., et al. (2014) Proof of Concept: Enthesitis and New Bone Formation in Spondyloarthritis Are Driven by Mechanical Strain and Stromal Cells. Annals of the Rheumatic Diseases, 73, 437-445. 
&lt;br&gt;https://doi.org/10.1136/annrheumdis-2013-203643</mixed-citation></ref><ref id="hanspub.33074-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Paulissen, S.M., van Hamburg, J.P., Davelaar, N., et al. (2013) Synovial Fibroblasts Directly Induce Th17 Pathogenicity via the Cyclooxygenase/Prostaglandin E2 Pathway, In-dependent of IL-23. The Journal of Immunology, 191, 1364-1372. &lt;br&gt;https://doi.org/10.4049/jimmunol.1300274</mixed-citation></ref><ref id="hanspub.33074-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Bergqvist, F., Carr, A.J., Wheway, K., et al. (2019) Divergent Roles of Prostacyclin and PGE2 in Human Tendinopathy. Arthritis Research &amp; Therapy, 21, 74. &lt;br&gt;https://doi.org/10.1186/s13075-019-1855-5</mixed-citation></ref><ref id="hanspub.33074-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Gaffen, S.L. (2009) Structure and Signalling in the IL-17 Recep-tor Family. Nature Reviews Rheumatology, 9, 556-567. 
&lt;br&gt;https://doi.org/10.1038/nri2586</mixed-citation></ref><ref id="hanspub.33074-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Amatya, N., Garg, A.V. and Gaffen, S.L. (2017) IL-17 Signaling: The Yin and the Yang. Trends in Immunology, 38, 310-322. &lt;br&gt;https://doi.org/10.1016/j.it.2017.01.006</mixed-citation></ref><ref id="hanspub.33074-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Aggarwal, S., Ghilardi, N., Xie, M.H., de Sauvage, F.J. and Gurney, A.L. (2003) Interleukin-23 Promotes a Distinct CD4 T Cell Acti-vation State Characterized by the Production of Interleukin-17. The Journal of Biological Chemistry, 278, 1910-1914. &lt;br&gt;https://doi.org/10.1074/jbc.M207577200</mixed-citation></ref><ref id="hanspub.33074-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Kenna, T.J., Davidson, S.I., Duan, R., et al. (2012) Enrichment of Circulating Interleukin-17-Secreting Interleukin-23 Receptor-Positive Gamma/Delta T Cells in Patients with Active An-kylosing Spondylitis. Arthritis &amp; Rheumatism, 64, 1420-1429. &lt;br&gt;https://doi.org/10.1002/art.33507</mixed-citation></ref><ref id="hanspub.33074-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">McGonagle, D.G., McInnes, I.B., Kirkham, B.W., Sherlock, J. and Moots, R. (2019) The Role of IL-17A in Axial Spondyloarthritis and Psoriatic Arthritis: Recent Advances and Controversies. Annals of the Rheumatic Diseases, 78, 1167-1178. &lt;br&gt;https://doi.org/10.1136/annrheumdis-2019-215356</mixed-citation></ref><ref id="hanspub.33074-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Reinhardt, A., Yevsa, T., Worbs, T., et al. (2016) Inter-leukin-23-Dependent Gamma/Delta T Cells Produce Interleukin-17 and Accumulate in the Enthesis, Aortic Valve, and Ciliary Body in Mice. Arthritis &amp; Rheumatology, 68, 2476-2486. &lt;br&gt;https://doi.org/10.1002/art.39732</mixed-citation></ref><ref id="hanspub.33074-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Cuthbert, R.J., Fragkakis, E.M., Dunsmuir, R., et al. (2017) Brief Report: Group 3 Innate Lymphoid Cells in Human Enthesis. Ar-thritis &amp; Rheumatology, 69, 1816-1822. &lt;br&gt;https://doi.org/10.1002/art.40150</mixed-citation></ref><ref id="hanspub.33074-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Buonocore, S., Ahern, P.P., Uhlig, H.H., et al. (2010) Innate Lymphoid Cells Drive Interleukin-23-Dependent Innate Intestinal Pathology. Nature, 464, 1371-1375. &lt;br&gt;https://doi.org/10.1038/nature08949</mixed-citation></ref><ref id="hanspub.33074-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Geremia, A., Arancibia-Carcamo, C.V., Fleming, M.P., et al. (2011) IL-23-Responsive Innate Lymphoid Cells Are Increased in Inflammatory Bowel Disease. The Journal of Experi-mental Medicine, 208, 1127-1133.  
&lt;br&gt;https://doi.org/10.1084/jem.20101712</mixed-citation></ref><ref id="hanspub.33074-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Bridgewood, C., Watad, A., Russell, T., et al. (2019) Identification of Myeloid Cells in the Human Enthesis as the Main Source of Local IL-23 Production. Annals of the Rheumatic Diseases, 78, 929-933.  
&lt;br&gt;https://doi.org/10.1136/annrheumdis-2018-214944</mixed-citation></ref><ref id="hanspub.33074-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Sherlock, J.P., Joyce-Shaikh, B., Turner, S., et al. (2013) Interleukin 23 Is Critical in the Pathogenesis of Spondyloarthropathy and Acts on a Novel Population of Interleukin 23R+ Entheseal Resident Cells. The Lancet, 381, S14. 
&lt;br&gt;https://doi.org/10.1016/S0140-6736(13)60454-7</mixed-citation></ref><ref id="hanspub.33074-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Sherlock, J.P., Joyce-Shaikh, B., Turner, S.P., et al. (2012) IL-23 Induces Spondyloarthropathy by Acting on ROR-Gammat+ CD3+CD4−CD8− Entheseal Resident T Cells. Nature Medicine, 18, 1069-1076. 
&lt;br&gt;https://doi.org/10.1038/nm.2817</mixed-citation></ref><ref id="hanspub.33074-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Brown, M.A., Kenna, T. and Wordsworth, B.P. (2016) Genetics of Anky-losing Spondylitis—Insights into Pathogenesis. Nature Reviews Rheumatology, 12, 81-91. &lt;br&gt;https://doi.org/10.1038/nrrheum.2015.133</mixed-citation></ref><ref id="hanspub.33074-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Siebert, S., Millar, N.L. and McInnes, I.B. (2019) Why Did IL-23p19 Inhibition Fail in AS: A Tale of Tissues, Trials or Translation? Annals of the Rheumatic Diseases, 78, 1015-1018. &lt;br&gt;https://doi.org/10.1136/annrheumdis-2018-213654</mixed-citation></ref><ref id="hanspub.33074-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">van Tok, M.N., Na, S., Lao, C.R., et al. (2018) The Initiation, but Not the Persistence, of Experimental Spondyloarthritis Is Dependent on Interleukin-23 Signaling. Frontiers in Immunology, 9, 1550. 
&lt;br&gt;https://doi.org/10.3389/fimmu.2018.01550</mixed-citation></ref><ref id="hanspub.33074-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Loi, F., Cordova, L.A., Pajarinen, J., et al. (2016) Inflammation, Fracture and Bone Repair. Bone, 86, 119-130. 
&lt;br&gt;https://doi.org/10.1016/j.bone.2016.02.020</mixed-citation></ref><ref id="hanspub.33074-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Olsen, B.R., Reginato, A.M. and Wang, W. (2000) Bone Devel-opment. Annual Review of Cell and Developmental Biology, 16, 191-220. &lt;br&gt;https://doi.org/10.1146/annurev.cellbio.16.1.191</mixed-citation></ref><ref id="hanspub.33074-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Wozney, J.M. (1998) The Bone Morphogenetic Protein Family: Multifunctional Cellular Regulators in the Embryo and Adult. European Journal of Oral Sciences, 106, 160-166. &lt;br&gt;https://doi.org/10.1111/j.1600-0722.1998.tb02170.x</mixed-citation></ref><ref id="hanspub.33074-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Waite, K.A. and Eng, C. (2003) From Developmental Disorder to Heritable Cancer: It’s All in the BMP/TGF-Beta Family. Nature Reviews Genetics, 4, 763-773. &lt;br&gt;https://doi.org/10.1038/nrg1178</mixed-citation></ref><ref id="hanspub.33074-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Lories, R.J., Daans, M., Derese, I., et al. (2006) Noggin Haploinsufficiency Differentially Affects Tissue Responses in Destructive and Remodeling Arthritis. Arthritis &amp; Rheumatism, 54, 1736-1746. &lt;br&gt;https://doi.org/10.1002/art.21897</mixed-citation></ref><ref id="hanspub.33074-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Lories, R.J., Derese, I. and Luyten, F.P. (2005) Modulation of Bone Morphogenetic Protein Signaling Inhibits the Onset and Progression of Ankylosing Enthesitis. Journal of Clinical Investigation, 115, 1571-1579.  
&lt;br&gt;https://doi.org/10.1172/JCI23738</mixed-citation></ref><ref id="hanspub.33074-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Rauner, M., Baschant, U., Roetto, A., et al. (2019) Transferrin Receptor 2 Controls Bone Mass and Pathological Bone Formation via BMP and Wnt Signaling. Nature Metabolism, 1, 111-124. &lt;br&gt;https://doi.org/10.1038/s42255-018-0005-8</mixed-citation></ref><ref id="hanspub.33074-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Bennett, C.N., Ouyang, H., Ma, Y.L., et al. (2007) Wnt10b In-creases Postnatal Bone Formation by Enhancing Osteoblast Differentiation. Journal of Bone and Mineral Research, 22, 1924-1932. &lt;br&gt;https://doi.org/10.1359/jbmr.070810</mixed-citation></ref><ref id="hanspub.33074-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Moon, R.T., Kohn, A.D., De Ferrari, G.V. and Kaykas, A. (2004) WNT and Beta-Catenin Signalling: Diseases and Therapies. Nature Reviews Genetics, 5, 691-701. &lt;br&gt;https://doi.org/10.1038/nrg1427</mixed-citation></ref><ref id="hanspub.33074-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Piters, E., Boudin, E. and Van Hul, W. (2008) WNT Signaling: A Win for Bone. Archives of Biochemistry and Biophysics, 473, 112-116. &lt;br&gt;https://doi.org/10.1016/j.abb.2008.03.006</mixed-citation></ref><ref id="hanspub.33074-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Day, T.F., Guo, X., Garrett-Beal, L., et al. (2005) WNT/Beta-Catenin Signaling in Mesenchymal Progenitors Controls Osteo-blast and Chondrocyte Differentiation during Vertebrate Skeletogenesis. Developmental Cell, 8, 739-750. 
&lt;br&gt;https://doi.org/10.1016/j.devcel.2005.03.016</mixed-citation></ref><ref id="hanspub.33074-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Kawano, Y. and Kypta, R. (2000) Secreted Antagonists of the WNT Signalling Pathway. Journal of Cell Science, 116, 2627-2634. &lt;br&gt;https://doi.org/10.1242/jcs.00623</mixed-citation></ref><ref id="hanspub.33074-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Li, X., Liu, P., Liu, W., et al. (2005) Dkk2 Has a Role in Terminal Osteoblast Differentiation and Mineralized Matrix Formation. Nature Genetics, 37, 945-952. &lt;br&gt;https://doi.org/10.1038/ng1614</mixed-citation></ref><ref id="hanspub.33074-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Haynes, K.R., Pettit, A.R., Duan, R., et al. (2012) Excessive Bone Formation in a Mouse Model of Ankylosing Spondylitis Is Associated with Decreases in WNT Pathway Inhibitors. Arthritis Research &amp; Therapy, 14, R253.  
&lt;br&gt;https://doi.org/10.1186/ar4096</mixed-citation></ref><ref id="hanspub.33074-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Heiland, G.R., Appel, H., Poddubnyy, D., et al. (2012) High Level of Func-tional Dickkopf-1 Predicts Protection from syNdesmophyte Formation in Patients with Ankylosing Spondylitis. Annals of the Rheumatic Diseases, 71, 572-574. 
&lt;br&gt;https://doi.org/10.1136/annrheumdis-2011-200216</mixed-citation></ref><ref id="hanspub.33074-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Yang, J., Andre, P., Ye, L. and Yang, Y.-Z. (2015) The Hedgehog Signalling Pathway in Bone Formation. International Journal of Oral Science, 7, 73-79. &lt;br&gt;https://doi.org/10.1038/ijos.2015.14</mixed-citation></ref><ref id="hanspub.33074-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Ruiz-Heiland, G., Horn, A., Zerr, P., et al. (2012) Blockade of the Hedgehog Pathway Inhibits Osteophyte Formation in Arthritis. Annals of the Rheumatic Diseases, 71, 400-407. &lt;br&gt;https://doi.org/10.1136/ard.2010.148262</mixed-citation></ref><ref id="hanspub.33074-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Dittmann, K., Wuelling, M., Uhmann, A., et al. (2014) Inactivation of Patched1 in Murine Chondrocytes Causes Spinal Fusion without Inflammation. Arthritis &amp; Rheumatology, 66, 831-840. &lt;br&gt;https://doi.org/10.1002/art.38325</mixed-citation></ref><ref id="hanspub.33074-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Daoussis, D., Filippopoulou, A., Liossis, S.N., et al. (2015) An-ti-TNFalpha Treatment Decreases the Previously Increased Serum Indian Hedgehog Levels in Patients with Ankylosing Spondylitis and Affects the Expression of Functional Hedgehog Pathway Target Genes. Seminars in Arthritis and Rheumatism, 44, 646-651.  
&lt;br&gt;https://doi.org/10.1016/j.semarthrit.2015.01.004</mixed-citation></ref><ref id="hanspub.33074-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">Chen, X., Macica, C., Nasiri, A., Judex, S. and Broadus, A.E. (2007) Mechanical Regulation of PTHrP Expression in Entheses. Bone, 41, 752-759. &lt;br&gt;https://doi.org/10.1016/j.bone.2007.07.020</mixed-citation></ref><ref id="hanspub.33074-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">Han, X., Guo, L., Wang, F., Zhu, Q.S. and Yang, L. (2014) Con-tribution of PTHrP to Mechanical Strain-Induced Fibrochondrogenic Differentiation in Entheses of Achilles Tendon of Miniature Pigs. Journal of Biomechanics, 47, 2406-2414. &lt;br&gt;https://doi.org/10.1016/j.jbiomech.2014.04.022</mixed-citation></ref><ref id="hanspub.33074-ref45"><label>45</label><mixed-citation publication-type="other" xlink:type="simple">Han, X., Zhuang, Y., Zhang, Z., Guo, L. and Wang, W. (2016) Regulatory Mechanisms of the Ihh/PTHrP Signaling Pathway in Fibrochondrocytes in Entheses of Pig Achilles Tendon. Stem Cells International, 2016, Article ID: 8235172. &lt;br&gt;https://doi.org/10.1155/2016/8235172</mixed-citation></ref><ref id="hanspub.33074-ref46"><label>46</label><mixed-citation publication-type="other" xlink:type="simple">Mouterde, G., Aegerter, P., Correas, J.M., et al. (2014) Value of Contrast-Enhanced Ultrasonography for the Detection and Quantifica-tion of Enthesitis Vascularization in Patients with Spondyloarthritis. Arthritis Care &amp; Research, 66, 131-138. &lt;br&gt;https://doi.org/10.1002/acr.22195</mixed-citation></ref><ref id="hanspub.33074-ref47"><label>47</label><mixed-citation publication-type="other" xlink:type="simple">Hakeda, Y., Nakatani, Y., Kurihara, N., et al. (1985) Prostaglandin E2 Stimulates Collagen and Non-Collagen Protein Synthesis and Prolyl Hydroxylase Activity in Osteoblastic Clone MC3T3-E1 Cells. Biochemical and Biophysical Research Communications, 126, 340-345. &lt;br&gt;https://doi.org/10.1016/0006-291X(85)90611-4</mixed-citation></ref><ref id="hanspub.33074-ref48"><label>48</label><mixed-citation publication-type="other" xlink:type="simple">Lie, E., Kristensen, L.E., Forsblad-d’Elia, H., et al. (2015)The Effect of Comedication with Conventional Synthetic Disease Modifying Antirheumatic Drugs on TNF Inhib-itor Drug Survival in Patients with Ankylosing Spondylitis and Undifferentiated Spondyloarthritis: Results from a Na-tionwide Prospective Study. Annals of the Rheumatic Diseases, 74, 970-978. &lt;br&gt;https://doi.org/10.1136/annrheumdis-2014-206616</mixed-citation></ref><ref id="hanspub.33074-ref49"><label>49</label><mixed-citation publication-type="other" xlink:type="simple">Gladman, D.D., Kavanaugh, A., Gomez-Reino, J.J., et al. (2018) Therapeutic Benefit of Apremilast on Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: A Pooled Anal-ysis of the PALACE 1-3 Studies. RMD Open, 4, e669. 
&lt;br&gt;https://doi.org/10.1136/rmdopen-2018-000669</mixed-citation></ref><ref id="hanspub.33074-ref50"><label>50</label><mixed-citation publication-type="other" xlink:type="simple">Marzo-Ortega, H., McGonagle, D., Jarrett, S., et al. (2005) Infliximab in Combination with Methotrexate in Active Ankylosing Spondylitis: A Clinical and Imaging Study. Annals of the Rheumatic Diseases, 64, 1568-1575. 
&lt;br&gt;https://doi.org/10.1136/ard.2004.022582</mixed-citation></ref><ref id="hanspub.33074-ref51"><label>51</label><mixed-citation publication-type="other" xlink:type="simple">McInnes, I.B., Kavanaugh, A., Gottlieb, A.B., et al. (2013) Efficacy and Safety of Ustekinumab in Patients with Active Psoriatic Arthritis: 1 Year Results of the Phase 3, Multicentre, Dou-ble-Blind, Placebo-Controlled PSUMMIT 1 Trial. The Lancet, 382, 780-789. &lt;br&gt;https://doi.org/10.1016/S0140-6736(13)60594-2</mixed-citation></ref><ref id="hanspub.33074-ref52"><label>52</label><mixed-citation publication-type="other" xlink:type="simple">Dubash, S., Bridgewood, C., McGonagle, D. and Mar-zo-Ortega, H. (2019) The Advent of IL-17A Blockade in Ankylosing Spondylitis: Secukinumab, Ixekizumab and Be-yond. Expert Review of Clinical Immunology, 15, 123-134.  
&lt;br&gt;https://doi.org/10.1080/1744666X.2019.1561281</mixed-citation></ref></ref-list></back></article>